|
Jul 25
|
Why Weight Loss Drug Developer Stocks Tumbled on Thursday
|
|
Jul 25
|
AstraZeneca Says It Has A 'Powerful' — And Differentiated — Approach To Obesity Treatment
|
|
Jul 25
|
Roche (RHHBY) Sales, Earnings Grow in 1H24, '24 EPS View Raised
|
|
Jul 25
|
Roche says it’ll move quickly with ‘differentiated’ obesity drugs
|
|
Jul 25
|
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised
|
|
Jul 23
|
Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?
|
|
Jun 19
|
Ascidian and Roche to develop RNA therapies for neurological diseases
|
|
Jun 18
|
Roche gains 501(k) clearance for digital pathology solution for diagnostic use
|
|
Jun 18
|
Roche partners with RNA editing biotech Ascidian
|
|
Jun 18
|
Roche receives FDA clearance on its digital pathology solution for diagnostic use
|
|
Jun 17
|
Roche (RHHBY) Reports Upbeat Data on Columvi From STARGLO Study
|
|
Jun 17
|
Roche’s Columvi offers extended survival in Phase III DLBCL trial
|
|
Jun 17
|
EHA 2024: Roche’s Columvi competes in BiTE battle with positive results in DLBCL
|
|
Jun 15
|
Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
|
|
Jun 15
|
Genentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
|
|
Apr 7
|
10 Best Weight Loss Drug Stocks to Buy Now
|
|
Apr 5
|
Should Weakness in Roche Holding AG's (VTX:ROG) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
|
|
Mar 29
|
15 Biggest Swiss Companies
|
|
Mar 28
|
Roche wins FDA approval for first molecular malaria blood donor screening test
|
|
Mar 27
|
Viking (VKTX) Up 17% on Encouraging Oral Obesity Drug Data
|